###begin article-title 0
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
BCoR-L1 variation and breast cancer
###end article-title 0
###begin p 1
This is an open access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Introduction
###end title 2
###begin p 3
###xml 207 212 207 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 214 217 214 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53</italic>
###xml 219 222 219 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM</italic>
###xml 224 229 224 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2</italic>
###xml 235 241 235 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRIP1 </italic>
###xml 613 621 613 621 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 690 698 690 698 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
BRCA1 is involved in numerous essential processes in the cell, and the effects of BRCA1 dysfunction in breast cancer carcinogenesis are well described. Many of the breast cancer susceptibility genes such as BRCA2, p53, ATM, CHEK2, and BRIP1 encode proteins that interact with BRCA1. BCL6 corepressor-like 1 (BCoR-L1) is a newly described BRCA1-interacting protein that displays high homology to several proteins known to be involved in the fundamental processes of DNA damage repair and transcription regulation. BCoR-L1 has been shown to play a role in transcription corepression, and expression of the X-linked BCoR-L1 gene has been reported to be dysregulated in breast cancer subjects. BCoR-L1 is located on the X chromosome and is subject to X inactivation.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 37 45 37 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1/2 </italic>
###xml 160 168 160 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 209 217 209 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 463 471 463 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
We performed mutation analysis of 38 BRCA1/2 mutation-negative breast cancer families with male breast cancer, prostate cancer, and/or haplotype sharing around BCoR-L1 to determine whether there is a role for BCoR-L1 as a high-risk breast cancer predisposition gene. In addition, we conducted quantitative real-time PCR (qRT-PCR) on lymphoblastoid cell lines (LCLs) from the index cases from these families and a number of cancer cell lines to assess the role of BCoR-L1 dysregulation in cancer and cancer families.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 92 100 92 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 274 280 274 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DIDO1 </italic>
###xml 331 337 331 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH </italic>
###xml 384 388 384 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UBC </italic>
###xml 179 187 <span type="species:ncbi:9606">patients</span>
Very little variation was detected in the coding region, and qRT-PCR analysis revealed that BCoR-L1 expression is highly variable in cancer-free subjects, high-risk breast cancer patients, and cancer cell lines. We also report the investigation of a new expression control, DIDO1 (death inducer-obliterator 1), that is superior to GAPDH (glyceraldehyde-3-phosphate dehydrogenase) and UBC (ubiquitin C) for analysis of expression in LCLs.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 25 33 25 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
Our results suggest that BCoR-L1 expression does not play a large role in predisposition to familial breast cancer.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 94 100 94 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 104 110 104 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 141 142 141 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 143 144 143 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 248 252 248 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 269 270 269 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 330 333 330 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM</italic>
###xml 342 343 342 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 404 408 404 408 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTEN</italic>
###xml 417 418 417 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 549 555 549 555 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 556 557 556 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 585 591 585 591 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRIP1 </italic>
###xml 604 609 604 609 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BACH1</italic>
###xml 612 613 612 613 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 619 625 619 625 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PALB2 </italic>
###xml 626 627 626 627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 628 629 628 629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
Less than 40% of familial breast cancer can be attributed to mutations in the high-risk genes BRCA1 and BRCA2 despite their high penetrance [1,2]. Syndromes displaying a predisposition for breast cancer such as Li-Fraumeni syndrome (resulting from p53 gene mutations) [3], ataxia telangiectasia (ataxia telangiectasia-mutated, or ATM, gene) [4], and Cowden syndrome (phosphatase and tensin homologue, or PTEN, gene) [5] are estimated to account for no more than 10% of familial breast cancer collectively, and additional moderate-risk genes such as CHEK2 [6] and the recently reported BRIP1 (also called BACH1) [7] and PALB2 [8,9] account for an even smaller percentage. This leaves a large proportion of the genetic basis of familial breast cancer unexplained.
###end p 11
###begin p 12
###xml 431 437 431 437 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 583 589 583 589 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 638 640 638 640 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 871 882 871 882 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila </italic>
###xml 1045 1047 1045 1047 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1149 1151 1149 1151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 1382 1384 1382 1384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 871 881 <span type="species:ncbi:7227">Drosophila</span>
Interestingly, BRCA2, p53, ATM, CHEK2, and BRIP1 all interact with the multifunctional tumour suppressor, BRCA1. BRCA1-interacting proteins are logical breast cancer candidates for two reasons. First, they are likely to be involved in some of the important roles of BRCA1 such as genome maintenance, transcription regulation, and cell cycle control and, if mutated, may result in the same highly penetrant and damaging effect as a BRCA1 mutation. Second, mutations in these interacting genes may prevent BRCA1 from performing vital functions, resulting in the same acute effect as a BRCA1 mutation itself. Recently, Pagan and colleagues [10] described the characterisation and functional analysis of a novel BRCA1-interacting protein, BCL6 corepressor-like 1 (BCoR-L1), that displays homology to several proteins involved in pathways such as DNA damage repair (BARD1 and Drosophila recombination repair protein 1) and transcription regulation (BCoR). Functional analysis thus far has revealed a role for BCoR-L1 in transcriptional corepression [10], placing it in a large group of proteins involved in the regulation of proliferation and apoptosis [11]. It is well established that uncontrolled overexpression of oncogenes and repression or mutation of tumour suppressors contribute to tumourigenesis by disturbing these vitally important and tightly controlled cellular processes [12].
###end p 12
###begin p 13
###xml 383 385 383 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 502 504 502 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
Evidence that BCoR-L1 operates primarily as a transcription corepressor includes its ability to dramatically reduce reporter gene expression through an interaction with the CtBP (carboxyl-terminal binding protein) corepressor via a PLDLS motif and the fact that it associates with a number of class II histone deacetylases (HDACs), factors also involved in transcription repression [10]. Similarly, BRCA1 interacts with a number of proteins involved in chromatin remodelling and transcription control [13]. Like BRCA1, BCoR-L1 is also involved in maintaining genomic stability after DNA damage.
###end p 13
###begin p 14
###xml 297 299 297 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 311 319 311 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 406 414 406 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1/2 </italic>
###xml 471 473 471 473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 493 501 493 501 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 639 641 639 641 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 642 644 642 644 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 647 655 647 655 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 694 696 694 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 801 803 801 803 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 821 829 821 829 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1/2 </italic>
###xml 848 853 848 853 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCAX</italic>
###xml 863 865 863 865 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 866 868 866 868 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
In addition to its interaction with BRCA1, there is indirect evidence to suggest that BCoR-L1 may behave as a tumour suppressor. The BCoR-L1 protein appears to be expressed ubiquitously at low levels (including breast tissue), with high levels in reproductive tissues such as prostate and testes [10]. However, BCoR-L1 expression was found to be decreased in a variety of breast cancer subjects, including BRCA1/2 mutation carriers and 'sporadic' breast cancer subjects [14]. In addition, the BCoR-L1 gene is located at Xq26.1, a region reported to exhibit loss of heterozygosity (LOH) in many tumour types, including those of the breast [15-17]. BCoR-L1 is subject to complete X inactivation [18], and interestingly, an increased frequency of skewed X inactivation has been reported in both ovarian [19] and early-onset BRCA1/2 mutation-negative (BRCAX) breast [20,21] cancer populations. It has been proposed that skewed X inactivation could provide a novel mechanism for nonrandom expression of a mutant tumour suppressor gene and thereby contribute to tumourigenesis.
###end p 14
###begin p 15
###xml 51 59 51 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 157 163 157 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCAX </italic>
###xml 658 666 658 666 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 721 723 721 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 837 845 837 845 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 1071 1079 1071 1079 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 1133 1141 1133 1141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 1206 1214 1206 1214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 1386 1394 1386 1394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 1467 1475 1467 1475 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
We sought to determine whether there is a role for BCoR-L1 as a high-risk breast cancer predisposition gene by screening the coding region of the gene in 38 BRCAX breast cancer families by means of the highly sensitive mutation detection technique, denaturing high-performance liquid chromatography (DHPLC). The majority of families were chosen specifically for the presence of male breast cancer and/or early-onset prostate cancer, in combination with being a high-risk female breast cancer family, for two reasons. We hypothesised that an X-linked gene may be involved in these male cancer because males carry only one copy of the X chromosome and because BCoR-L1 has been found to be expressed highly in the prostate [10]. A small number of breast cancer families in which the affected individuals showed haplotype sharing around the BCoR-L1 locus were also included in this study. In addition, we conducted quantitative real-time PCR (qRT-PCR) on lymphoblastoid cell lines (LCLs) from members of these families and a number of cancer cell lines to assess the role of BCoR-L1 expression in cancer and cancer families. We assessed BCoR-L1 expression in LCLs from breast cancer cases to determine whether BCoR-L1 expression was altered in familial breast cancer cases and, if so, whether this was associated with the presence of genetic variation. Analysis of X inactivation status of BCoR-L1 was also undertaken in order to assess the likely mode of inheritance of BCoR-L1 as a candidate tumour suppressor gene.
###end p 15
###begin title 16
Materials and methods
###end title 16
###begin title 17
X inactivation status analysis
###end title 17
###begin p 18
###xml 52 60 52 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 596 604 596 604 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 81 86 <span type="species:ncbi:9606">human</span>
###xml 170 175 <span type="species:ncbi:10090">mouse</span>
###xml 176 181 <span type="species:ncbi:9606">human</span>
###xml 193 198 <span type="species:ncbi:9606">human</span>
###xml 230 235 <span type="species:ncbi:9606">human</span>
###xml 316 321 <span type="species:ncbi:9606">human</span>
###xml 546 551 <span type="species:ncbi:9606">human</span>
X inactivation status was assessed by comparison of BCoR-L1 mRNA expression with human-specific primers (forward: CATATGATGTGACGGAATCTC; reverse: CCCTGGACTTTGTTGGGCA) in mouse-human or hamster-human hybrid cell lines containing a human active X chromosome (AHA-11aB1, A23-1aC1I5, t60-12, GM06318D, CHO-01416-M) or a human inactive X chromosome (LT23-1E2, t48-1a-1Daz4a, t11-4Aaz5, t75-2maz34-1a, t86-B1maz1b-3a, X8-6T2S1, CHO-01416-07). Comparison of expression levels between the two groups of cell lines (containing an inactive versus inactive human X chromosome) was used to establish whether BCoR-L1 is subject to X inactivation.
###end p 18
###begin title 19
Subjects
###end title 19
###begin p 20
###xml 159 161 159 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 338 340 338 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 401 407 401 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 410 416 410 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 423 428 423 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCAX</italic>
###xml 786 788 786 788 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 1159 1161 1159 1161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 1698 1700 1698 1700 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 1810 1818 1810 1818 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 1941 1949 1941 1949 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 1981 1989 1981 1989 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 2109 2111 2109 2111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 2214 2220 2214 2220 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
Multiple-case breast cancer families were ascertained through the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab) [22]. Inclusion criteria for all families in this study required that the family be classified as category 3 (high-risk) according to the National Breast Cancer Centre guidelines [23] and that the family not possess any known mutations in the BRCA1 or BRCA2 genes (BRCAX) at the time of initiation of the study. Ethics approvals were obtained from the ethics committees of the Peter MacCallum Cancer Institute (East Melbourne, Victoria, Australia) and the Queensland Institute of Medical Research (Brisbane, Queensland, Australia), and all subjects gave written informed consent. Male breast cancer families selected for study (n = 21) all contained one or more male breast cancer cases occurring on the same side of the family as at least three female breast cancer cases. A total of 11 male breast cancer cases and 16 female index cases (the youngest breast cancer case in the family from which biospecimens were available) were screened from these families. Prostate/female breast cancer families (n = 12) were chosen to contain at least one 'early-onset' prostate cancer case (cancer diagnosed at not more than 60 years of age) on the same side of the family as three or more female breast cancer cases. A total of 2 prostate cancer cases and 12 index female breast cancer cases were analysed from these families. Pedigrees were examined to ensure the absence of male-to-male transmission of the disease in these families because this would imply involvement of an autosomal gene. Additionally, families with female breast cancer only (n = 7) were selected for analysis because they demonstrated haplotype sharing in the same chromosomal region as BCoR-L1 (DXS1001, DXS1047, and DXS1227; LOD [logarithm of the odds] score greater than 0.5; data not shown) and are referred to as BCoR-L1 haplotype sharing families. Two BCoR-L1 variants were found in one family and were then genotyped in all family members from which biospecimens were available (n = 12). Mutation screening in the kConFab cohort during the course of the study subsequently identified BRCA2 mutation carriers in two male breast cancer families. Control subjects (46 females and 55 males) without cancer or a family history of cancer included subjects ascertained via the Queensland Blood Bank and a group of geriatric controls (average age of 80 years).
###end p 20
###begin title 21
###xml 14 22 14 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
Screening for BCoR-L1 variation
###end title 21
###begin p 22
###xml 258 266 258 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 334 342 334 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 448 450 448 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 459 460 459 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 871 872 869 870 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 902 906 900 904 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Taq </italic>
###xml 1020 1021 1018 1019 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 1112 1113 1110 1111 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1603 1605 1589 1591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1614 1615 1600 1601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
BCoR-L1 is expressed in two isoforms. The most common isoform is 1,711 amino acids in size and lacks exon 9, but the full-length protein (1,785 amino acids long) is derived from the alternative transcript. This study screened the entire coding region of the BCoR-L1 gene, including exon 9. Primers encompassing the 13 coding exons of BCoR-L1 (and surrounding intronic regions; GenBank: exons 2 to 8: ; exons 9 to 14: ) were designed using Primer3 [24] (Table 1). Exon 4 was too large to be amplified at an optimal size for DHPLC analysis and was therefore analysed with 10 overlapping polymerase chain reaction (PCR) fragments. 'Standard' PCR reactions were carried out in a 20-mul mixture containing 15 ng of genomic DNA, and a final concentration of 20 pmol of each primer, 200 muM each of dATP, dCTP, dGTP, and dTTP (Promega Corporation, Madison, WI, USA), 1.5 mM MgCl2, 1x PCR buffer, and 1 U AmpliTaq Gold polymerase (PE Applied Biosystems, Foster City, CA, USA). Any variation to the reaction is detailed in Table 1, along with a description of 'touchdown' PCR amplification conditions. All products (and H2O controls) were visualised on a 1.5% agarose gel. Male samples were mixed with sequence-confirmed wild-type female PCR product (2:1) to encourage heteroduplexes to form for successful DHPLC analysis. Samples were denatured by heating to 95degreesC for 5 minutes and cooling to 60degreesC over a period of 30 minutes and then analysed on a Varian Helix DHPLC system (Varian, Inc., Palo Alto, CA, USA) at the recommended melt temperature(s) as determined by the Stanford DHPLC Melt program [25] (Table 1). Analysis of results was carried out using Star Workstation Reviewer software (version 5, Varian) and any aberrant or shifted profiles were reamplified for confirmation of the aberrant profile by repeat DHPLC before being sequenced using the Big-Dye (version 3.1) sequencing chemistry and PE Applied Biosystems 377 sequencer.
###end p 22
###begin p 23
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCOR-L1 </italic>
BCOR-L1 polymerase chain reaction conditions
###end p 23
###begin p 24
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 234 235 222 223 <sub xmlns:xlink="http://www.w3.org/1999/xlink">A</sub>
###xml 354 355 330 331 <sub xmlns:xlink="http://www.w3.org/1999/xlink">A</sub>
###xml 392 394 368 370 <sub xmlns:xlink="http://www.w3.org/1999/xlink">A </sub>
###xml 429 431 399 401 <sub xmlns:xlink="http://www.w3.org/1999/xlink">A </sub>
###xml 477 478 441 442 <sub xmlns:xlink="http://www.w3.org/1999/xlink">A</sub>
a'Touchdown' polymerase chain reaction (PCR) amplification conditions were as follows: denaturation at 94degreesC for 10 minutes, followed by two cycles of 94degreesC for 30 seconds, 30 seconds at the fragment annealing temperature (TA) + 6degreesC, and 72degreesC for 30 seconds. The conditions remained the same for the rest of the PCR except for the TA, which consisted of two cycles at (TA + 4degreesC), then two cycles at (TA + 2degreesC), and (finally) 35 cycles at the TA. A final extension step was conducted at 72degreesC for 7 minutes. bp, base pairs; DHPLC, denaturing high-performance liquid chromatography.
###end p 24
###begin title 25
Loss of heterozygosity analysis
###end title 25
###begin p 26
###xml 55 63 55 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 377 379 377 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
LOH analysis was carried out on tumour blocks from the BCoR-L1 haplotype sharing family carrying the exon 4 c.516T>C variant, because genotyping analysis revealed that the variant segregated with breast cancer. Macrodissected tumour and adjacent cancer-uninvolved tissue DNA was extracted from tumour blocks by means of a modified version of the method of Levi and colleagues [26], and 2 mul of each DNA (plus 20 ng of lymphocyte-derived germline DNA from the same subject) was then added to separate 20-mul PCR reactions, as detailed above. Primers used were (forward) TCAACACCCAAATGAGCAAA and (reverse) GAACAGAGTGGGGCACAGAG to give a product of 242 base pairs. 'Touchdown' PCR was used with an annealing temperature of 50degreesC. PCR products were then purified (Qiagen Inc., Valencia, CA, USA) and sequenced. LOH was evaluated by scoring the absence of the allele in the sequencing trace of the tumour, compared to matching germline DNA.
###end p 26
###begin title 27
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
BCoR-L1 expression analysis
###end title 27
###begin p 28
###xml 169 171 169 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a</xref>
###xml 420 422 419 421 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 762 763 759 760 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 1440 1446 1405 1411 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH </italic>
###xml 1463 1469 1428 1434 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DIDO1 </italic>
###xml 1582 1584 1547 1549 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t </italic>
###xml 87 91 <span type="species:ncbi:9913">calf</span>
All LCLs and normal and cancer cell lines were grown in RPMI 1640 media with 10% fetal calf serum and 1% penicillin/streptomycin. Cell lines used are detailed in Figure 1a. RNA was extracted from LCLs and cell lines using TriReagent (Sigma-Aldrich, St. Louis, MO, USA) according to the manufacturer's instructions, and 1 mug of each sample was placed in a reverse transcription-PCR reaction using Superscript III RNAse H- Reverse Transcriptase as directed by the manufacturer (Invitrogen Corporation, Carlsbad, CA, USA). qRT-PCR was then carried out in a 15 mul reaction containing a final volume of 20 ng of cDNA, 20 pmol of each primer, and 7.5 mul of Platinum SYBR Green qPCR Supermix UDG (Invitrogen Corporation). Primer sequences used are detailed in Table 2. qRT-PCR conditions were 50degreesC for 2 minutes and 95degreesC for 2 minutes, 40 cycles of 95degreesC for 20 seconds, 60degreesC for 15 seconds, and 72degreesC for 20 seconds (acquiring) on a Rotor-Gene RG-3000 Real-Time PCR machine (Corbett Research Australia, Mortlake, New South Wales, Australia). All samples were run in duplicate and were repeated if profiles did not replicate according to Rotor-Gene analysis software (version 5). Accordingly, the maximum standard deviation allowed for a pair of duplicates ('Rep. Ct Std. Dev' in analysis software) was low (</=0.2). Expression levels were presented as the mean of two duplicates, normalised to expression of either GAPDH (all samples) or DIDO1 (death inducer-obliterator 1) (LCLs only). Expression levels of different groups were compared using the Student t test (two-tailed).
###end p 28
###begin p 29
Quantitative real-time polymerase chain reaction primer sequences
###end p 29
###begin p 30
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1</italic>
###xml 34 39 34 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DIDO1</italic>
###xml 70 75 70 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH</italic>
###xml 119 122 119 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UBC</italic>
BCoR-L1, BCL6 corepressor-like 1; DIDO1, death inducer-obliterator 1; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; UBC, ubiquitin C.
###end p 30
###begin p 31
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 0 50 0 50 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>BCoR-L1 </italic>expression in cancer and normal cell lines</bold>
###xml 52 56 52 56 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 56 64 56 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 108 112 108 112 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 143 151 143 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 291 298 291 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1</italic>
###xml 325 330 325 330 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH</italic>
BCoR-L1 expression in cancer and normal cell lines. (a) BCoR-L1 expression in cancer and normal cell lines. (b) Mean and standard deviation of BCoR-L1 expression in cancer and normal cell lines. Normal cell lines: ovarian - OSE 64/96, HOSE 17.1; breast - SVCT, Bre80hTERT; prostate - RWPE1. BCoR-L1, BCL6 corepressor-like 1; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
###end p 31
###begin title 32
Assessment of expression controls for lymphoblastoid cell lines
###end title 32
###begin p 33
###xml 326 337 326 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-actin </italic>
###xml 341 347 338 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH </italic>
###xml 456 458 453 455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 604 610 601 607 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH </italic>
###xml 627 630 624 627 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UBC</italic>
###xml 656 658 653 655 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 909 911 906 908 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1094 1100 1091 1097 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DIDO1 </italic>
RT-PCR expression controls are typically chosen for their stability of expression not only during various phases of the cell cycle, but also between different tissue types. However, it is well known that these characteristics are very difficult to obtain. It has been reported that widely accepted expression controls such as beta-actin and GAPDH show unacceptable variation in expression in a large number of tissues and are therefore not ideal controls [27]. We sought to find a suitable expression control for analysis of expression in LCLs and compared this with two widely used expression controls, GAPDH and ubiquitin C (UBC). Cheung and colleagues [28] used microarray analysis to establish the variability of expression of 5,184 genes in LCLs taken from random individuals. We evaluated the 100 least variably expressed genes for suitability as an LCL expression control for our project via a PubMed [29] search of the literature to identify the genes that (a) had not been reported to be associated with cancer of any kind and (b) were not in a region of LOH or linkage to any cancer. DIDO1 was chosen according to these criteria.
###end p 33
###begin title 34
Results and Discussion
###end title 34
###begin p 35
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 396 398 396 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 468 471 468 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Rb </italic>
###xml 523 525 523 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 545 553 545 553 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 676 684 676 684 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
BCoR-L1 was selected as an interesting breast cancer candidate gene for a number of reasons. BCoR-L1 interacts with the important breast cancer susceptibility gene product, BRCA1, and there is the possibility that BCoR-L1 is involved, with BRCA1, in critical DNA repair and cell growth pathways. Indeed, mutations in repressor proteins have been implicated in several diseases, including cancer [30]. For example, functional mutations in the transcriptional repressor Rb gene result in dysregulation of cell cycle control [31]. In addition, the BCoR-L1 gene is located at Xq26.1, a region that exhibits LOH in cancers, including breast cancer, and there is some evidence that BCoR-L1 mRNA expression is deregulated in breast cancer. Skewed X inactivation has been reported in breast and ovarian cancer subjects, indicating the possible presence of an X-linked cancer predisposition gene.
###end p 35
###begin title 36
X inactivation status analysis
###end title 36
###begin p 37
###xml 46 54 46 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 298 306 298 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 417 419 417 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 451 458 451 458 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UTP14A </italic>
###xml 500 508 500 508 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCOR-L1 </italic>
###xml 586 594 586 594 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCOR-L1 </italic>
###xml 654 662 654 662 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 743 751 743 751 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 349 355 <span type="species:ncbi:9606">humans</span>
Analysis of the hybrid cell lines showed that BCoR-L1 was not expressed in 4/5 hybrid cell lines containing an inactive X chromosome and was expressed at very low levels in the fifth cell line t48-1a-1Daz4a, using hybrids containing an active X chromosome as reference. These results indicate that BCoR-L1 is subject to X chromosome inactivation in humans, which is in agreement with the study of Carrel and Willard [18], who showed that the proximal UTP14A gene was expressed in 3/9 hybrids whereas BCOR-L1 (FLJ11362) was silent in all 9. As some of the hybrids in this study overlap, BCOR-L1 is silenced in 11/11 hybrids studied to date. The fact that BCoR-L1 is subject to X inactivation suggests that only a single mutational event in the BCoR-L1 gene would be required to initiate tumourigenesis.
###end p 37
###begin title 38
###xml 17 25 17 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
Variation in the BCoR-L1 gene
###end title 38
###begin p 39
###xml 39 47 39 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 77 83 77 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCAX </italic>
###xml 162 163 162 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 291 299 291 299 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 389 390 389 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 546 556 546 556 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in silico </italic>
###xml 611 613 611 613 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 694 696 694 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 789 791 789 791 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 962 964 962 964 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 1196 1198 1196 1198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 670 675 <span type="species:ncbi:10090">mouse</span>
###xml 679 682 <span type="species:ncbi:10116">rat</span>
###xml 1060 1065 <span type="species:ncbi:9606">human</span>
DHPLC analysis of the coding region of BCoR-L1 in 48 members of 38 high-risk BRCAX breast cancer families revealed only four different sequence variations (Table 3). A nucleotide variation in exon 4 (c.516T>C; p.N172N) was found in one breast cancer family known to share a haplotype at the BCoR-L1 locus. This variant was carried primarily by breast cancer cases from this family (Figure 2). However, this c.516T>C nucleotide substitution is not likely to be functional because it does not result in an amino acid change and is not predicted by in silico modelling to have any effect on mRNA structure (MFOLD [32]) and the wild-type T allele is not conserved in either mouse or rat (PipMaker [33]). Investigation of exonic splice enhancer (ESE) sites by means of ESEfinder (version 2.0) [34] revealed that the variant allele produces an SC35 site (of value 2.455), but this score is very close to the SC35 threshold of 2.383. Similar analysis using Rescue ESE [35] revealed no change. Additionally, analysis of codon usage of the AAT codon (wild-type) in the human genome versus the AAC codon (variant) showed that the two codons are used at similar frequencies (16.8 versus 19.1/1,000 codons) [36]. Finally, LOH analysis of the c.516T>C variant gave no evidence of the change being involved in tumourigenesis. LOH analysis of tumour blocks and germline DNA from all four breast cancer cases in this family revealed either loss of the variant allele or no LOH (data not shown), indicating that this variant is unlikely to be pathogenic.
###end p 39
###begin p 40
###xml 26 34 26 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
Variation detected in the BCoR-L1 gene
###end p 40
###begin p 41
###xml 213 221 213 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 258 259 258 259 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 300 301 300 301 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 340 341 340 341 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 402 407 402 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2</italic>
###xml 409 416 409 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1</italic>
Three samples were included in both the male breast cancer family and prostate cancer family categories because they fitted both criteria. Two samples were similarly included in both male breast cancer family and BCoR-L1 haplotype sharing family categories. aMales carrying a variant are homozygous. bReported in dbSNP or SNPper databases. cOne of the variant-carrying subjects possesses a mutation in BRCA2. BCoR-L1, BCL6 corepressor-like 1.
###end p 41
###begin p 42
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 0 103 0 103 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>BCoR-L1 </italic>haplotype sharing family pedigree detailing carriers of the c.516T&gt;C and c.3608-156C&gt;T variants</bold>
###xml 402 409 397 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1</italic>
BCoR-L1 haplotype sharing family pedigree detailing carriers of the c.516T>C and c.3608-156C>T variants.  = breast cancer-positive; c.516T>C and c.3608-156C>T-positive.  = breast cancer-negative; c.516T>C and c.3608-156C>T-positive. square = breast cancer-negative; c.516T>C and c.3608-156C>T-negative. Circle = female, square = male; subjects marked by small shapes were not available for genotyping. BCoR-L1, BCL6 corepressor-like 1.
###end p 42
###begin p 43
###xml 133 134 133 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 338 340 338 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 396 404 396 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 744 748 744 748 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a,b</xref>
The intron 5 c.3608-156C>T variant was found only in members of the family who carried the exon 4 synonymous variant p.N172N (Figure 2). Due to its deeply intronic location, c.3608-156C>T is not predicted to have any functional effect. SpliceSiteFinder did not predict any changes to splicing as a result of this nucleotide substitution [37]. Furthermore, mRNA expression analysis (see below) of BCoR-L1 in two of the variant-carrying breast cancer cases and one wild-type non-breast cancer subject from this family revealed no evidence for consistent differences in expression in LCLs. Relative to the unaffected wild-type family control, one variant carrier displayed increased expression and the other displayed decreased expression (Figure 3a,b; subjects marked with #).
###end p 43
###begin p 44
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 0 82 0 82 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>BCoR-L1 </italic>expression in lymphoblastoid cell lines (LCLs) from breast cancer families</bold>
###xml 84 88 84 88 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 88 96 88 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 158 163 158 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH</italic>
###xml 166 170 166 170 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 170 178 170 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 240 246 240 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DIDO-1</italic>
###xml 249 253 249 253 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 284 292 284 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 361 369 361 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 393 398 393 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH</italic>
###xml 401 405 401 405 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(d) </bold>
###xml 436 444 436 444 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 513 521 513 521 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 545 551 545 551 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DIDO-1</italic>
###xml 578 584 578 584 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
###xml 594 595 594 595 <sup xmlns:xlink="http://www.w3.org/1999/xlink">#</sup>
###xml 618 626 618 626 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 652 659 652 659 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1</italic>
###xml 686 692 686 692 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DIDO-1</italic>
###xml 723 728 723 728 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH</italic>
BCoR-L1 expression in lymphoblastoid cell lines (LCLs) from breast cancer families. (a) BCoR-L1 expression in LCLs from breast cancer families (normalised to GAPDH). (b) BCoR-L1 expression in LCLs from breast cancer families (normalised to DIDO-1). (c) Mean and standard deviation of BCoR-L1 expression in samples, grouped according to type of family cancer or BCoR-L1 genotype (normalised to GAPDH). (d) Mean and standard deviation of BCoR-L1 expression in samples, grouped according to type of family cancer or BCoR-L1 genotype (normalised to DIDO-1). *Subject also carries a BRCA2 mutation. #Subjects from the same BCoR-L1 haplotype sharing family. BCoR-L1, BCL6 corepressor-like 1; DIDO-1, death inducer-obliterator 1; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
###end p 44
###begin p 45
###xml 50 58 50 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 304 312 304 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 502 504 502 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 639 641 639 641 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 678 686 678 686 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 825 829 825 829 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3c,d</xref>
###xml 966 972 966 972 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA2 </italic>
The two other variants detected in and around the BCoR-L1 coding region in this study, c.625G>A (p.G209S) and c.5075+21C>T, were found in similar frequencies in the control sample. Similarly, there were no major differences between groups when the study sample was divided into male breast, prostate, or BCoR-L1 haplotype sharing families. Although the exon 4 p.G209S variant is a missense amino acid substitution, this change is predicted by SIFT (Sorting Intolerant From Tolerant) to be 'tolerated' [38]. p.G209S is also located in a region of BCoR-L1 that is not thought to be involved in BRCA1 interaction or transcription repression [10]. Additionally, qRT-PCR analysis of BCoR-L1 expression in breast cancer cases carrying the p.G209S and c.5075+21C>T variants showed no differences when compared with controls (Figure 3c,d), with overlapping standard deviations for expression. Furthermore, both variants were present in individuals found to carry pathogenic BRCA2 mutations during the course of the study.
###end p 45
###begin p 46
###xml 105 113 105 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 205 213 205 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 339 341 339 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 342 344 342 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
Overall, we detected very little variation in the coding region (and surrounding intronic region) of the BCoR-L1 gene in our population of familial cancer cases. The low level of variation detected in the BCoR-L1 gene is consistent with reports that the X chromosome carries very little variation when compared with autosomal chromosomes [39-41].
###end p 46
###begin title 47
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
BCoR-L1 expression analysis
###end title 47
###begin p 48
###xml 35 43 35 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 174 182 174 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 221 229 221 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 506 508 506 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 536 538 536 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 679 687 679 687 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
To further investigate the role of BCoR-L1 in familial breast cancer and male cancers, we undertook qRT-PCR expression analysis on LCLs from subjects previously screened for BCoR-L1 coding region variation. Alteration of BCoR-L1 expression in LCLs from breast cancer-affected family members may indicate the presence of a regulatory mutation in a noncoding region of the gene. In addition, since various HDACs are aberrantly expressed in a number of cancers susceptible to treatment using HDAC inhibitors [42], including breast cancer [43], we speculated that BCoR-L1, given its association with HDACs, might also be abnormally expressed in breast cancer cases. We thus assessed BCoR-L1 expression in a range of breast, ovarian, and prostate cancer lines.
###end p 48
###begin title 49
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DIDO1 </italic>
DIDO1 expression in lymphoblastoid cell lines and cell lines
###end title 49
###begin p 50
###xml 34 40 34 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DIDO1 </italic>
###xml 96 101 96 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DIDO1</italic>
###xml 103 108 103 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH</italic>
###xml 114 118 114 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UBC </italic>
###xml 160 164 160 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4a,b</xref>
###xml 196 202 196 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DIDO1 </italic>
###xml 251 257 251 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH </italic>
###xml 260 263 260 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UBC</italic>
###xml 270 276 270 276 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH </italic>
###xml 280 284 280 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UBC </italic>
###xml 339 341 339 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4a</xref>
###xml 372 378 372 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DIDO1 </italic>
###xml 424 428 424 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UBC </italic>
###xml 432 437 432 437 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH</italic>
###xml 570 576 570 576 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH </italic>
###xml 620 622 620 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4b</xref>
###xml 636 642 636 642 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DIDO1 </italic>
###xml 734 740 734 740 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH </italic>
To investigate the suitability of DIDO1 as an LCL expression control, we analysed expression of DIDO1, GAPDH, and UBC in all LCLs and cell lines tested (Figure 4a,b). Interestingly, we found that DIDO1 expression varies considerably less in LCLs than GAPDH or UBC, with GAPDH and UBC showing similar levels of expression variation (Figure 4a). The interquartile range for DIDO1 was 2.5-fold and 2.7-fold less than those for UBC and GAPDH, respectively. In cancer cell lines, all three expression control genes showed large ranges of expression levels across lines, with GAPDH perhaps showing the least variation (Figure 4b). Therefore, DIDO1 is an improved expression control for LCLs but has variability similar to the commonly used GAPDH control in normal and cancer cell lines.
###end p 50
###begin p 51
###xml 0 36 0 36 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Variation in control gene expression</bold>
###xml 38 42 38 42 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 109 113 109 113 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 165 171 165 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DIDO-1</italic>
###xml 202 207 202 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH</italic>
###xml 251 254 251 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UBC</italic>
Variation in control gene expression. (a) Variation in control gene expression in lymphoblastoid cell lines. (b) Variation in control gene expression in cell lines. DIDO-1, death inducer-obliterator 1; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; UBC, ubiquitin C.
###end p 51
###begin title 52
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
BCoR-L1 expression in lymphoblastoid cell lines from breast cancer families
###end title 52
###begin p 53
###xml 158 166 158 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 223 231 223 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 298 302 298 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a&#8211;d</xref>
###xml 328 336 328 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 657 665 657 665 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 776 778 776 778 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 824 832 824 832 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 961 967 961 967 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH </italic>
###xml 975 979 975 979 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a,c</xref>
###xml 984 990 984 990 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DIDO1 </italic>
###xml 998 1002 998 1002 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3b,d</xref>
###xml 1086 1092 1086 1092 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DIDO1 </italic>
###xml 1146 1152 1146 1152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DIDO1 </italic>
###xml 1288 1294 1288 1294 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DIDO1 </italic>
###xml 1308 1313 1308 1313 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH</italic>
###xml 1340 1348 1340 1348 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 1509 1517 1509 1517 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
Twenty-nine LCLs from breast cancer cases and their family members (23 families in total, including 14 with male breast cancer, 7 with prostate cancer, and 2 BCoR-L1 haplotype sharing families) were analysed for changes in BCoR-L1 expression when compared with LCLs from 6 healthy controls (Figure 3a-d). Although expression of BCoR-L1 appeared to be greatly variable, there were no apparent differences in expression levels between breast cancer cases and controls, nor were there any differences between groups when segregated by family cancer type (that is, male breast, prostate, and so on). Likewise, there was no indication of any association between BCoR-L1 genotype and expression. Skewed X chromosome inactivation data were available for a limited number of samples (n = 8). However, skewing did not correlate with BCoR-L1 expression or genotype (data not shown). Results correlating expression with sample source or sample genotype were similar using GAPDH (Figure 3a,c) or DIDO1 (Figure 3b,d) normalisation, although the decreased variability observed in normal controls for DIDO1 normalisation supported our earlier observations that DIDO1 is an improved control for LCL expression analysis. The standard deviation of expression in control LCLs was approximately 20% less for DIDO1 compared with GAPDH. Overall, it appears that BCoR-L1 expression is not altered in familial breast cancer cases, even for subgroups defined by male cancer type, and it is unlikely that there is any variation in the BCoR-L1 gene (detected or otherwise) which has a profound effect on expression.
###end p 53
###begin title 54
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
BCoR-L1 expression in cancer and normal cell lines
###end title 54
###begin p 55
###xml 30 38 30 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 74 82 74 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 171 175 171 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a,b</xref>
###xml 303 311 303 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 489 497 489 497 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 740 748 740 748 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 749 751 749 751 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1170 1172 1170 1172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1253 1266 1253 1266 <italic xmlns:xlink="http://www.w3.org/1999/xlink">upregulation </italic>
###xml 1326 1333 1326 1333 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1</italic>
###xml 1435 1443 1435 1443 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 1476 1478 1476 1478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 1629 1637 1629 1637 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
To assess a possible role for BCoR-L1 in tumourigenesis, we also analysed BCoR-L1 expression in various ovarian, breast, and prostate cancer and normal cell lines (Figure 1a,b). Most normal and cancer cell lines exhibited increased expression levels compared with LCLs. Once again, it was observed that BCoR-L1 expression is highly variable in both cancer and normal cell lines, with up to 13-fold differences in expression observed. There were no significant differences between the mean BCoR-L1 expression in normal cell lines compared with cancer cell lines, but individual ovarian and breast cancer cell lines showed significantly increased expression compared with the mean expression in normal cell lines. Markedly elevated levels of BCoR-L1 (P < 0.05) were observed for a total of 4/10 ovarian cancer cell lines (OVCAR3, SKOV3, A2780, 27/87; 4-fold to 13-fold upregulation compared with the HOSE17.1 normal ovarian epithelial control) and 2/13 breast cancer cell lines (BT20 and T47D; 3-fold and 4-fold upregulation compared with SVCT normal breast control). This was interesting, considering that skewed X inactivation has been reported in ovarian cancer cases [19]. It would also seem to suggest that dysregulation of expression in the form of upregulation may play a role in tumourigenesis. However, a study using a BCoR-L1-containing Affymetrix microarray (Affymetrix, Santa Clara, CA, USA) did not provide any evidence for BCoR-L1 deregulation in ovarian cancers [44]. Comparison of gene expression between 37 advanced-stage serous ovarian carcinomas and normal ovarian surface epithelium cytobrushings revealed that BCoR-L1 was not one of 1,191 genes that were significantly differentially regulated (defined as greater than or equal to 1.5-fold change in expression). This contrasts with the 4- to 13-fold increased expression we observed for specific cancer lines compared with normal ovarian epithelial cell lines.
###end p 55
###begin p 56
###xml 95 103 95 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 253 261 253 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 339 341 339 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 460 468 460 468 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 469 471 469 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 593 601 593 601 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 682 684 682 684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 696 703 696 703 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1</italic>
###xml 910 917 910 917 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1</italic>
###xml 1070 1078 1070 1078 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 1090 1092 1090 1092 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 1093 1095 1093 1095 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 1115 1123 1115 1123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 1501 1503 1501 1503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 1504 1506 1504 1506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
There was no evidence that the hormone receptor status of each cell line correlated with these BCoR-L1 expression differences because the highly estrogen receptor (ER)- and progesterone receptor (PR)-positive breast cancer cell line T47D showed similar BCoR-L1 expression to BT20, a breast cancer cell line that does not express ER or PR [45]. In addition, the ovarian cancer cell lines OVCAR3 (ER-positive) and SKOV3 (ER-negative) expressed similar levels of BCoR-L1 [46]. Investigation of the X chromosome karyotype of these ovarian cancer cell lines did reveal a possible relationship with BCoR-L1 expression. Karyotype data were available for OVCAR3, SKOV3, OVCAR5, and OVCAR8 [47], with the BCoR-L1-overexpressing lines OVCAR3 and SKOV3 found to possess three copies of Xq and four X chromosomes, respectively. Conversely, OVCAR5 and OVCAR8 each possess only one X chromosome and express normal levels of BCoR-L1. Information on the X chromosome karyotype of breast cancer cell lines was limited, but there was no indication of an association between karyotype and BCoR-L1 expression [47,48]. The finding that BCoR-L1 expression tends to correlate with supernumary X chromosomes suggests that this overexpression probably does not contribute to carcinogenesis but may occur as a result of carcinogenesis. Although it is unknown whether the superfluous X chromosomes in OVCAR3 and SKOV3 are active, it has been reported that ovarian (and breast) tumours can possess multiple active X chromosomes [48-51].
###end p 56
###begin title 57
Conclusion
###end title 57
###begin p 58
###xml 68 76 68 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 173 181 173 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1/2 </italic>
###xml 340 347 340 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1</italic>
###xml 503 511 503 511 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 784 792 784 792 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 917 925 917 925 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
###xml 1042 1048 1042 1048 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHEK2 </italic>
###xml 1049 1050 1049 1050 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 1053 1059 1053 1059 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRIP1 </italic>
###xml 1060 1061 1060 1061 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 1068 1074 1068 1074 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PALB2 </italic>
###xml 1075 1076 1075 1076 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1077 1078 1077 1078 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1100 1106 1100 1106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCAX </italic>
###xml 1145 1153 1145 1153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1 </italic>
The aim of the present study was to attempt to elucidate a role for BCoR-L1 as a high-risk breast cancer predisposition gene by mutation screening of well-characterised non-BRCA1/2 familial breast cancer subjects who were selected to maximise the probability of identifying a mutation. We detected minimal variation in the coding region of BCoR-L1, which may imply the importance of maintaining the structural integrity of the BCoR-L1 protein. It is also unlikely that noncoding region variation in the BCoR-L1 gene is involved in breast cancer predisposition as we did not detect any significant changes in expression between cancer cases and cell lines and controls. The absence of pathogenic coding mutations or expression deregulation in this set of familial cases indicates that BCoR-L1 is extremely unlikely to be a major high-risk familial breast cancer predisposition gene. However, it is still possible that BCoR-L1 could be involved in breast cancer predisposition as a moderate- or low-penetrance risk gene, as has been found with CHEK2 [6], BRIP1 [7], and PALB2 [8,9] in large studies of BRCAX cases and controls. The involvement of BCoR-L1 in ovarian cancer may also be worthy of investigation, and further functional analysis of the BCoR-L1 protein will help to elucidate the involvement of BCoR-L1 in various essential pathways.
###end p 58
###begin title 59
Abbreviations
###end title 59
###begin p 60
###xml 72 78 72 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCAX </italic>
###xml 80 88 80 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1/2 </italic>
###xml 166 172 166 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DIDO1 </italic>
###xml 257 263 257 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH </italic>
###xml 611 615 611 615 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UBC </italic>
ATM = ataxia telangiectasia-mutated; BCoR-L1 = BCL6 corepressor-like 1; BRCAX = BRCA1/2 mutation-negative; DHPLC = denaturing high-performance liquid chromatography; DIDO1 = death inducer-obliterator 1; ER = estrogen receptor; ESE = exonic splice enhancer; GAPDH = glyceraldehyde-3-phosphate dehydrogenase; HDAC = histone deacetylase; kConFab = Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer; LCL = lymphoblastoid cell line; LOH = loss of heterozygosity; PCR = polymerase chain reaction; PR = progesterone receptor; qRT-PCR = quantitative real-time polymerase chain reaction; UBC = ubiquitin C.
###end p 60
###begin title 61
Competing interests
###end title 61
###begin p 62
The authors declare that they have no competing interests.
###end p 62
###begin title 63
Authors' contributions
###end title 63
###begin p 64
###xml 398 405 398 405 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCoR-L1</italic>
FL carried out the screening of the gene and the LOH and expression analysis and drafted the manuscript. JA provided RNA from all of the breast and ovarian cell lines. GJM and GMP performed haplotype sharing analysis. CJB performed the X inactivation status analysis and drafted the relevant section of the manuscript. DBY contributed to the experimental study design and provided sequence data on BCoR-L1. kConFab recruited and collected subjects for the study. GC-T and KKK participated in the design and coordination of the study. ABS conceived the study, participated in its design and coordination, and helped to draft the manuscript. All authors read and approved the final manuscript.
###end p 64
###begin title 65
Acknowledgements
###end title 65
###begin p 66
The authors thank Heather Thorne, Eveline Niedermayr, Lynda Williams, Danni Surace, and all the kConFab research nurses and staff, the heads and staff of the Family Cancer Clinics, and the Clinical Follow Up Study (funded by National Health and Medical Research Council [NHMRC] grants 145684 and 288704) for their contributions to this resource and the many families who contribute to kConFab. kConFab is supported by grants from the National Breast Cancer Foundation and the NHMRC and by the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania, and South Australia, and the Cancer Foundation of Western Australia. The authors thank Helene Holland for supplying data and Anna Marsh for technical advice and assistance on DHPLC. Judith Clements and Ying Dong supplied prostate cancer cell lines used in this study, and Vivien G Cheung kindly made available unpublished data on mRNA expression levels in LCLs. This research was supported by grants from the Queensland Cancer Fund and National Breast Cancer Foundation. GC-T and KKK are NHMRC Principal Research Fellows, and ABS is funded by an NHMRC Career Development Award.
###end p 66
###begin article-title 67
###xml 48 56 <span type="species:ncbi:9606">patients</span>
Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer
###end article-title 67
###begin article-title 68
Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium
###end article-title 68
###begin article-title 69
Inherited p53 gene mutations in breast cancer
###end article-title 69
###begin article-title 70
Dominant negative ATM mutations in breast cancer families
###end article-title 70
###begin article-title 71
Inherited mutations in PTEN that are associated with breast cancer, cowden disease, and juvenile polyposis
###end article-title 71
###begin article-title 72
The CHEK2*1100delC allelic variant and risk of breast cancer: screening results from the Breast Cancer Family Registry
###end article-title 72
###begin article-title 73
Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles
###end article-title 73
###begin article-title 74
A recurrent mutation in PALB2 in Finnish cancer families
###end article-title 74
###begin article-title 75
PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene
###end article-title 75
###begin article-title 76
A novel corepressor, BCoR-L1, represses transcription through an interaction with CtBP
###end article-title 76
###begin article-title 77
Biological roles and mechanistic actions of co-repressor complexes
###end article-title 77
###begin article-title 78
The hallmarks of cancer
###end article-title 78
###begin article-title 79
BRCA1 gene in breast cancer
###end article-title 79
###begin article-title 80
Gene expression profiling predicts clinical outcome of breast cancer
###end article-title 80
###begin article-title 81
###xml 46 51 <span type="species:ncbi:9606">human</span>
Loss of heterozygosity on the X chromosome in human breast cancer
###end article-title 81
###begin article-title 82
###xml 67 72 <span type="species:ncbi:9606">human</span>
Loss of heterozygosity at chromosome segment Xq25-26.1 in advanced human ovarian carcinomas
###end article-title 82
###begin article-title 83
###xml 71 76 <span type="species:ncbi:9606">human</span>
Loss of heterozygosity on chromosome XP22.2-p22.13 and Xq26.1-q27.1 in human breast carcinomas
###end article-title 83
###begin article-title 84
X-inactivation profile reveals extensive variability in X-linked gene expression in females
###end article-title 84
###begin article-title 85
###xml 94 102 <span type="species:ncbi:9606">patients</span>
Association between nonrandom X-chromosome inactivation and BRCA1 mutation in germline DNA of patients with ovarian cancer
###end article-title 85
###begin article-title 86
###xml 63 71 <span type="species:ncbi:9606">patients</span>
High frequency of skewed X inactivation in young breast cancer patients
###end article-title 86
###begin article-title 87
###xml 60 68 <span type="species:ncbi:9606">patients</span>
High incidence of skewed X chromosome inactivation in young patients with familial non-BRCA1/BRCA2 breast cancer
###end article-title 87
###begin article-title 88
Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource
###end article-title 88
###begin article-title 89
Advice about familial aspects of breast cancer and epithelial ovarian cancer: a guide for health professionals
###end article-title 89
###begin article-title 90
Primer3 on the WWW for general users and for biologist programmers
###end article-title 90
###begin article-title 91
Optimal temperature selection for mutation detection by denaturing HPLC and comparison to single-stranded conformation polymorphism and heteroduplex analysis
###end article-title 91
###begin article-title 92
Multiple K-ras codon 12 mutations in cholangiocarcinomas demonstrated with a sensitive polymerase chain reaction technique
###end article-title 92
###begin article-title 93
Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes
###end article-title 93
###begin article-title 94
###xml 21 26 <span type="species:ncbi:9606">human</span>
Natural variation in human gene expression assessed in lymphoblastoid cells
###end article-title 94
###begin article-title 95
PubMed
###end article-title 95
###begin article-title 96
When enough is enough: genetic diseases associated with transcriptional derepression
###end article-title 96
###begin article-title 97
How mammalian transcriptional repressors work
###end article-title 97
###begin article-title 98
Mfold web server for nucleic acid folding and hybridization prediction
###end article-title 98
###begin article-title 99
PipMaker - a web server for aligning two genomic DNA sequences
###end article-title 99
###begin article-title 100
ESEfinder: a web resource to identify exonic splicing enhancers
###end article-title 100
###begin article-title 101
###xml 58 63 <span type="species:ncbi:9606">human</span>
Predictive identification of exonic splicing enhancers in human genes
###end article-title 101
###begin article-title 102
Codon usage tabulated from international DNA sequence databases: status for the year 2000
###end article-title 102
###begin article-title 103
Alex Dong Li's SpliceSiteFinder
###end article-title 103
###begin article-title 104
Predicting deleterious amino acid substitutions
###end article-title 104
###begin article-title 105
###xml 24 29 <span type="species:ncbi:9606">human</span>
The DNA sequence of the human X chromosome
###end article-title 105
###begin article-title 106
###xml 63 68 <span type="species:ncbi:9606">human</span>
Single nucleotide polymorphisms (SNPs) that map to gaps in the human SNP map
###end article-title 106
###begin article-title 107
###xml 23 28 <span type="species:ncbi:9606">human</span>
A haplotype map of the human genome
###end article-title 107
###begin article-title 108
Histone-deacetylase inhibitors: novel drugs for the treatment of cancer
###end article-title 108
###begin article-title 109
Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor alpha
###end article-title 109
###begin article-title 110
Whole genome expression profiling of advance stage papillary serous ovarian cancer reveals activated pathways
###end article-title 110
###begin article-title 111
###xml 70 78 70 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 82 90 82 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 36 41 <span type="species:ncbi:9606">human</span>
Heterogeneity of MUC1 expression by human breast carcinoma cell lines in vivo and in vitro
###end article-title 111
###begin article-title 112
Antiestrogens modulate MT1 melatonin receptor expression in breast and ovarian cancer cell lines
###end article-title 112
###begin article-title 113
Karyotypic complexity of the NCI-60 drug-screening panel
###end article-title 113
###begin article-title 114
Loss of the inactive X chromosome and replication of the active X in BRCA1-defective and wild-type breast cancer cells
###end article-title 114
###begin article-title 115
Clinical-cytological correlations of mammary carcinoma based upon sex-chromatin counts
###end article-title 115
###begin article-title 116
###xml 38 43 <span type="species:ncbi:9606">human</span>
Two identical active X chromosomes in human mammary carcinoma cells
###end article-title 116
###begin article-title 117
Global analysis of chromosome X gene expression in primary cultures of normal ovarian surface epithelial cells and epithelial ovarian cancer cell lines
###end article-title 117

